Wyeth's gemtuzumab
Executive Summary
On March 17, the committee will consider Wyeth-Ayerst's gemtuzumab zogamicin (NDA 21-174) for treatment of acute myeloid leukemia in patients who have relapsed after initial chemotherapy. The meetings will be at the Holiday Inn in Bethesda, Md., at 8:30 a.m. on March 16 and at 8:00 a.m. on March 17